Retinoic acid agonists inhibited tumor growth in vivo in ACC patient‐derived xenograft models and decreased MYB binding at translocated enhancers, thereby potentially diminishing the MYB positive feedback loop driving ACC [48]. This evidence concerns the gene MYB and adrenal cortex carcinoma.